Evaluation of immunotherapy strategies in mouse models of carcinoma is hampered by the limited number of known murine tumor antigens (Ags). Although tumor Ags can be identified based on cytotoxic T-cell activation, this approach is not readily accomplished for many tumor types. We applied an alternative strategy based on a humoral immune response, SEREX, to the identification of tumor Ags in the murine colon adenocarcinoma cell line MC38. Immunization of syngeneic C57BL/6 mice with MC38 cells by three different methods induced a protective immune response with concomitant production of anti-MC38 antibodies. Immunoscreening of an MC38-derived expression library resulted in the identification of the endogenous ecotropic leukemia virus envelope (env) protein and the murine ATRX protein as candidate tumor Ags. Northern blot analysis demonstrated high levels of expression of the env transcript in MC38 cells and in several other murine tumor cell lines, whereas expression in normal colonic epithelium was absent. ATRX was found to be variably expressed in tumor cell lines and in normal tissue. Further analysis of the expressed env sequence indicated that it represents a nonmutated tumor Ag. Polynucleotide immunization with DNA encoding the env polypeptide resulted in strong and specific antibody responses to this self Ag in all immunized mice. Thus, SEREX offers a rapid means of identifying tumor Ags in murine cancer models. Cancer Gene Therapy (2000) 7, 446 -455
T he concept of cancer immunotherapy is predicated on the existence of tumor-associated antigens (TAAs) against which the host is capable of mounting an immune response, leading to tumor rejection. To this end, immune responses in tumor-bearing individuals have been described for a variety of mutant tumor antigens (Ags), such as mutant p53 [1] [2] [3] and ras, 4 -7 as well as nonmutant tumor proteins including erbB-2, 8, 9 MART-1, 10,11 MAGE-1, 12,13 tyrosinase, 14, 15 and MUC-1. 16 Such tumor-specific responses suggest that the immune system may be amenable to strategies that further induce or enhance patients' immune responses to their own tumor cells. Important to the concept of developing effective immunotherapies is the ability to break immunological tolerance to self Ags. However, the ability to evaluate approaches for breaking tolerance to specific Ags in mouse models of cancer is limited by the fact that few murine tumor Ags have been described to date. Accordingly, many murine immunotherapy models use heterologous Ags (for example, Refs. [17] [18] [19] , which may not address issues critical to the development of effective immunotherapeutic strategies. A more complete understanding of the spectrum of murine Ags capable of eliciting antitumoral immune responses is needed to better understand the interaction of cancer and the immune system as well as for the development of more effective cancer vaccines.
Several methods have been employed to isolate and clone TAAs. Due to the critical role of cytotoxic T lymphocytes (CTLs) in mediating antitumoral immunity, these approaches have largely consisted of the isolation of Ags recognized by CTLs that have been expanded in vitro. Tumor Ags have been identified in this manner by acid elution of antigenic peptides bound to major histocompatibility complex class I molecules. 20 A second, genetic approach assays CTL responsiveness to target cells transfected with cDNA libraries to identify immunogenic peptides. 21, 22 Although these approaches have proven valuable for TAA identification in some tumor types, particularly human melanoma, widespread application is hampered by difficulties in establishing longterm CTL cultures. In addition, it has not yet been established that CTLs generated in vitro are representative of the tumor-specific CTLs in vivo. Thus, complementary approaches for the identification of novel immunogenic tumor Ags are warranted.
The activation of CTL responses is dependent upon T-helper (Th) cells and may be accompanied by the induction of humoral immunity. Indeed, humoral im-mune responses to known TAAs have been described in tumor-bearing individuals. 1, 2, [23] [24] [25] [26] [27] The presence of antibodies (Abs) directed toward known tumor Ags suggests the potential usefulness of serum for the identification of novel TAAs. The feasibility of such a strategy for identifying tumor Ags was demonstrated by Sahin et al, 28 who identified both known and novel tumor Ags using autologous sera from cancer patients to screen tumorderived expression libraries, an approach they termed "serologic identification of Ags by recombinant expression cloning" (SEREX). This technique has succeeded in greatly expanding the scope of human tumor Ags. 29 By comparison, the catalog of cloned mouse tumor Ags remains quite small.
Mouse models of syngeneic tumors provide a useful system in which to investigate the nature of TAAs. The MC38 colonic adenocarcinoma cell line was derived from C57BL/6 mice treated with the carcinogen 1,2-dimethylhydrazine. 30 These cells produce tumors when injected subcutaneously in syngenic mice, but immunization of naive syngeneic mice with MC38 cells can induce an immune response that mediates tumor rejection upon challenge with an otherwise lethal dose of live cells. Thus, these cells express cryptic tumor Ags that stimulate antitumoral immune responses in vivo. Here, we describe the application of SEREX technology toward the identification of MC38 Ags. This approach identified the endogenous ecotropic retroviral envelope (env) and the murine ATRX proteins as putative tumor Ags in these cells. These Ags were reactive with sera from mice immunized with MC38 cells in three different ways. The env protein was found to be a nonmutant tumor Ag, and polynucleotide immunization was used to demonstrate that an immune response could be elicited to this self Ag. These studies demonstrate the utility of SEREX as a means to rapidly identify murine tumor Ags for further evaluation in immunotherapy models.
MATERIALS AND METHODS

Cell lines and culture conditions
MC38 and MC38-CEA-2 31 cells were kindly provided by Dr. Steven Rosenberg (National Cancer Institute, Bethesda, Md) and were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf sera (FCS). B16 is a mouse melanoma cell line that arose spontaneously in C57BL/6 mice. 32 These cells were maintained in Eagle's minimal essential medium with 10% FCS. The mouse lymphoma cell line EL4, 33 a chemically induced line derived from a C57BL/6 mouse, was maintained in DMEM supplemented with 10% horse sera. The mouse mammary tumor cell lines 4T01 and 4T07 are sublines of a spontaneously arising mammary tumor in a BALB/cfC 3 H mouse; 34 both of these lines were maintained in DMEM/F12 supplemented with 10% FCS. CT26 cells are colonic adenocarcinoma cells from a BALB/c mouse induced by N-nitroso-N-methylurethane; 35 they were cultured in RPMI 1640 with 10% FCS. P815, a mastocytoma line derived from a DBA/2 mouse, 36 was maintained in RPMI 1640 with 10% FCS. C2C12, a mouse myoblast cell line (American Type Culture Collection, Manassas, Va), was maintained in DMEM with 10% FCS.
Immunization protocol
To elicit anti-MC38 immune responses, groups of 12 mice were immunized in one of three ways. Group I mice were injected with 5 ϫ 10 5 MC38 cells into the right foot pad and tumors were excised 10 -14 days later. A total of 10 of 12 mice survived the amputation and were available for challenge on day 29 with 3 ϫ 10 5 cells injected subcutaneously into the flank. A total of 8 of the 10 mice rejected the day 29 tumor challenge and received a second identical tumor challenge on day 79, followed 14 days later by exsanguination to harvest sera. Group II mice were injected subcutaneously on days 1 and 15 with 1 ϫ 10 6 MC38 cells that had been irradiated with 15,000 cGy. Mice were then challenged with 3 ϫ 10 5 nonirradiated tumor cells on day 29. A total of 3 of 12 animals developed tumors and were sacrificed. The remaining nine animals were rechallenged with 3 ϫ 10 5 nonirradiated tumor cells on day 54. Sera were collected from these animals 14 days later. Group III animals were immunized with a plasmid DNA encoding human carcinoembryonic Ag (CEA) and challenged with MC38 cells stably transfected to express human CEA (MC38-CEA-2 31 ). We have shown previously that polynucleotide immunization with a CEA-encoding plasmid results in reliable rejection of MC38-CEA-2 cells. 37 Thus, 12 mice received intramuscular injections of 50 g of plasmid-encoding CEA on days 1 and 15, followed by tumor challenge with 3 ϫ 10 5 MC38-CEA-2 cells on days 29, 41, and 54. A total of 8 of 12 mice successfully rejected all three challenges with MC38-CEA-2 cells, and sera were collected from these mice 14 days after the last challenge. In each of the three immunization experiments described above, tumors grew in 12 of 12 naive control mice, validating each challenge with MC38 or MC38-CEA-2 tumor cells.
Assay for Ab response to intact tumor cells
To determine whether the various immunization strategies had elicited an Ab response to MC38 tumor cells, a cell-binding assay was performed as described previously. 38 Briefly, tumor cells were washed with phosphate-buffered saline (PBS) and 5 ϫ 10 5 cells were aliquoted per tube in 100 L of PBS with 1% bovine serum albumin (PBE). Each tube then received 100 L of a 1/10 dilution of immune sera or normal mouse sera in PBE, and the cell/serum mixture was incubated at room temperature for 1 hour on an orbital shaker. Cells were then washed with 4 mL of PBS to remove unbound Ab. After washing, the cells were resuspended in 100 L of PBS containing 0.1% pigskin gelatin and 100 ng of 125 I-labeled Staphylococcus aureus protein A (SPA) (ϳ200,000 cpm per tube), and incubated for 1 hour at room temperature with shaking. SPA was obtained from Sigma (St. Louis, Mo) and was radiolabeled by the Iodogen method (Pierce, Rockford, Ill). The cells were washed with 4 mL of PBS and counted in a gamma scintillation counter. The specific activity of the 125 I-labeled SPA was used to convert counts per minute bound to the number of molecules bound per cell. 38 The SPA binding to cells incubated in PBE only (no sera) was subtracted as nonspecific binding. MC38-CEA-2 cells incubated with CEA-specific monoclonal Ab (COL-1) served as a positive control.
cDNA library construction and immunoscreening
Total RNA from MC38 cells or MC38-CEA-2 cells was isolated using an RNA Stat 60 RNA isolation reagent (TelTest B), and mRNA was isolated on oligo(dT) beads (PolyAQuik mRNA isolation kit, Stratagene, La Jolla, Calif). A cDNA library was constructed in the Zap Express vector (Stratagene), which is capable of directing expression in both prokaryotic and eukaryotic hosts. Briefly, mRNA was reverse transcribed using an oligo(dT) primer with an internal XhoI site as well as a random primers that included an XhoI restriction site at the end. The reverse transcription reaction included 5-methyl deoxycytidine triphosphate. After secondstrand synthesis, EcoRI adapters were added by ligation and the cDNA was restricted with XhoI. cDNA fragments were cloned into the directional Zap Express vector, packaged, and used to infect Escherichia coli cells. As a preliminary characterization of the library, inserts from random plaques were amplified by polymerase chain reaction (PCR) and demonstrated insert sizes ranging from ϳ300 bp to 3.5 kb with Ͼ90% recombinants (data not shown).
For immunoscreening, recombinant plaques were plated at a density of ϳ20,000 plaques per 150-mm plate, and protein expression was induced using nitrocellulose filters saturated with isopropyl ␤-D-thiogalactoside. Filters were lifted, blocked with 1% bovine serum albumin in Tris-buffered saline (20 mM tris(hydroxymethyl)aminomethane (Tris) (pH 7.5) and 150 mM NaCl), and screened with sera from mice immunized as described above to detect reactive plaques. Primary mouse sera were preabsorbed with E. coli phage lysate (Stratagene) and diluted 1/250 for screening. After incubating filters with diluted mouse sera, the filters were washed with Tris-buffered saline with 0.05% Tween 20 (Sigma) and incubated with alkaline phosphate-conjugated goat anti-mouse immunoglobulin G (IgG) Abs (Stratagene) at a dilution of 1/5000 for 1 hour at room temperature. After washing, a nitroblue tetrazolium/ 5-bromo-4-chloro-3-indolyl phosphate colorimetric substrate was used to identify positive clones. Positive plaques were purified to clonality for further study.
DNA sequencing
Phagemid DNA from positive plaques was rescued by in vivo excision using a helper phage system (Stratagene). Purified DNA was sequenced by dideoxy sequencing using Sequenase 2.0 (United States Biochemical, Cleveland, Ohio) and 35 Slabeled deoxyadenosine triphosphate. Approximately 250 bp of sequence were determined at both the 5Ј and 3Ј ends using T3 and T7 primers, respectively. Sequences were searched against the National Center for Biotechnology databases using the BLASTN program.
To sequence the env gene expressed in MC38 for comparison with C57BL/6 genomic sequences, PCR products were generated from reverse-transcribed MC38 total RNA and C57BL/6 genomic DNA. The 2.6-kb coding region was amplified using the following primers: 5Ј-GAGAAAAGCTTCGC-CCCCGATAAACCATGGAG-3Ј and 5Ј-GCGCAAGCTTT-GCACCAGCAAAAGGCTTTATT-3Ј. HindIII sites are italicized. Sequencing of the PCR products was performed using an ABT automated DNA sequencer (Perkin Elmer Biosystems, Foster City, Calif) with the PCR primers as well as internal sequencing primers.
Northern blot analysis
Total RNA was isolated from cultured cells using RNA Stat-60 (Tel-Test B) according to the manufacturer's directions. To isolate RNA from colonic epithelium, a section of colon was isolated and opened longitudinally; next, the epithelium was recovered by gentle scraping. Epithelial cells were homogenized in RNA Stat-60 and processed as for the cultured cells. Approximately 8 g of total RNA from each sample was electrophoresed on a 1% denaturing agarose gel and transferred to a nylon membrane (Amersham, Arlington Heights, Ill). The blot was prehybridized for 2 hours at 65°C in a solution of 6ϫ standard saline citrate (SSC), 5ϫ Denhardt's, 100 g/mL sheared salmon sperm DNA, 1 mM ethylenediaminetetraacetic acid (EDTA), and 0.5% sodium dodecyl sulfate (SDS). For analysis of env expression, 200 ng of a random-primed 32 P-deoxycytidine triphosphate-labeled probe was generated corresponding to bp 6004 -6543 of the env gene, a BglII to BamHI fragment. This probe recognizes only the ecotropic env sequence. 39, 40 For ATRX, the 2.8-kb insert was isolated and labeled. Each probe was hybridized overnight in hybridization solution as described above, with the probe at a concentration of 20 ng/mL. After hybridization, the blot was washed successively in 2ϫ SSC with 0.5% SDS, 2ϫ SSC with 0.1% SDS, and 0.1ϫ SSC with 0.1% SDS; next, the blot was autoradiographed at Ϫ70°C for a period of 1-4 days. To control for loading differences, the blot was stripped with boiling 0.1% SDS and rehybridized with a probe specific for the mouse ␤-actin gene (Stratagene).
Southern blot analysis
For Southern blot analysis, genomic DNA from MC38 cells, B16 cells, and normal colonic epithelial cells was isolated by lysis in 50 mM Tris (pH 8.0), 10 mM EDTA, 10 mM NaCl, and 1% SDS, and by treatment with 100 g/mL Proteinase K overnight at 50°C. After phenol/chloroform extraction, the DNA was precipitated with ethanol and resuspended in 10 mM Tris and 1 mM EDTA (pH 8.0). Approximately 10 g of DNA was subjected to digestion with the appropriate restriction enzyme, electrophoresed on a 1% agarose gel, and transferred to a nylon membrane (Amersham). The membrane was hybridized with an env-or an ATRX-specific probe as described above.
Polynucleotide immunization and isotype analysis
Groups of 10 mice were immunized with DNA encoding the 1.3-kb partial env cDNA or with vector backbone. Intramuscular injections of 50 g of plasmid DNA (at 1 mg/mL) were made on days 1, 15, and 29. Sera were collected 4 days after the third immunization for analysis of env-specific Ab via screening against the env-expressing plaques as described above. For isotype analysis, alkaline phosphatase-conjugated, isotype-specific Abs (Clonotyping System, Southern Biotechnology Associates, Birmingham, Ala), were used as secondary Abs at a dilution of 1/1000.
RESULTS
Immunization and detection of Abs directed against MC38 Ags
Three groups of mice were immunized to generate sera reactive with MC38 cells. Group I mice were injected with MC38 cells with subsequent tumor excision, and group II animals were immunized with irradiated MC38 cells. Both of these groups were then challenged with live MC38 cells, which were rejected by most animals (17 of 22) . A third group of animals was immunized with plasmid DNA encoding human CEA (pCEA) and challenged with MC38 cells expressing CEA, as reported previously. 37 A total of 8 of 12 animals in this group rejected three consecutive tumor challenges. After the immunization schedules were completed, the presence of MC38-reactive Abs was detected in an MC38 cellbinding assay (Fig 1) . All three groups of immunized mice demonstrated high levels of Ab binding to intact MC38 cells, whereas naive mouse sera did not. Mice immunized with pCEA and challenged with MC38-CEA-2 cells produced Abs to the parental MC38 cells in addition to CEA-specific Abs, as manifested by increased Ab binding to MC38-CEA-2 cells compared with parental MC38 cells. Thus, these serum samples contained Abs that were useful for detection of cryptic TAAs in MC38 cells.
Identification of reactive plaques
Sera from immunized animals (group III) were used to screen an MC38-derived cDNA library. Reactive plaques were then purified to homogeneity in secondary and tertiary screens. Screening of ϳ10 6 plaques resulted in the identification of two independent positive plaques. Amplification of the insert of one of these plaques by PCR demonstrated the presence of a 1.3-kb insert. Importantly, sera from animals immunized with MC38 cells by all three routes described above (groups I, II, and III) were strongly reactive with the 1.3-kb plaque (Fig 2) . Isotype analysis revealed that reactive Abs were predominantly IgG2a and IgG2b , with IgM and IgG1 being weakly reactive (data not shown). Dideoxy sequencing was performed on rescued plasmid DNA using the T3 and T7 primers present in the vector. A search of the National Center for Biotechnology database revealed the identity of the clone with a portion of the endogenous ecotropic leukemia proviral sequence (MuLV). This insert sequence includes the 3Ј portion of the env protein sequence (env) as well as the 3Ј long terminal repeat (LTR) (GenBank accession numbers J01998 and U63133) (Fig 2) . The clone contains base pairs 7071-8374 of the published sequence, 41 corresponding to amino acid 430 to the C terminus of the env protein. The env polypeptide encoded by this clone includes the last one-third of the extracellular portion of the protein, as well as the entire transmembrane domain. A 99-bp deletion of the 3Ј LTR was also noted, as discussed below.
The second plaque had an insert size of ϳ2.8 kb and was also reactive with all groups of MC38-immunized animals. Sequence analysis of the insert revealed that it represents a portion (base pairs 503-3327) of the murine homolog of the ATRX gene (accession number AF026032). This gene encodes a protein with potential DNA binding and helicase activity. 42, 43 The sequence of the 2.8-kb fragment derived from MC38 mRNA was not mutated compared with the published sequence.
Assessment of env and ATRX mRNA expression in murine tumor cells Northern blot analysis was performed to determine whether the env and ATRX genes are actively transcribed in MC38 cells (Fig 3) . Total RNA was isolated from MC38 cells and several other murine tumor cell lines. These included the C57BL/6-derived cell lines B16 (melanoma) and EL4 (lymphoma) as well as the BALB/cderived colonic line CT26 and the mammary tumor cell lines 4T1 and 4T07. The mastocytoma cell line P815 from DBA/2 mice was also analyzed, as was the nontransformed myoblast cell line C2C12. Total RNA was also isolated from the normal colonic epithelium of a C57BL/6 mouse. The endogenous ecotropic env gene was implicated previously as a melanoma-specific Ag in B16 cells. 44 High levels of env gene expression were detected in MC38, B16, CT26, and 4T07 cells (Fig 3A) . Expression was also noted in 4T1 and EL4, with very low levels of expression in P815 cells. Expression of the proviral sequences was not detected in the myoblast line C2C12 or in normal colonic epithelium. Thus, although not expressed in normal cells, the ecotropic endogenous retrovirus is expressed in a variety of murine tumor cell lines, including both spontaneously arising tumors (B16, 4T1, and 4T07) and carcinogen-induced tumors (MC38, EL4, P815, and CT26). The ATRX gene was found to be expressed in all of the cell lines tested, as well as in normal colonic epithelium (Fig 3B) . Expression was strongest in the tumor cell lines B16 and EL4.
Southern blot analysis
We subsequently investigated the genomic structure of the env-encoding proviral sequence in MC38 cells. Endogenous retroviruses may become activated as the result of a point mutation and remain single copy, 45 or activation may be accompanied by amplification or rearrangement of the proviral sequence.
46 C57BL/6 cells normally contain a single copy of the endogenous ecotropic proviral sequence, which resides on chromosome 8. 47 To determine whether this MuLV proviral sequence was amplified and/or rearranged in MC38 cells, Southern blot analysis was performed. Genomic DNA from normal colon, MC38 cells, and B16 cells was digested with the restriction enzymes BamHI, HindIII, PstI, PvuII, and KpnI. Hybridization of the DNA with the ecotropic-specific env probe revealed the presence of novel fragments in the MC38 DNA; these fragments were not found in the normal DNA and in some cases were distinct from those of B16 DNA (Fig 4) . This finding suggests that the MC38 proviral sequence has likely undergone amplification and reintegration into new genomic sites. Southern blot analysis of the ATRX gene revealed no apparent genomic rearrangements in MC38 or B16 cells compared with normal genomic DNA (data not shown).
Analysis of the env sequence
We chose to further study the env protein as a tumor Ag in this mouse model to determine the basis of its immunogenicity. To determine whether the env sequence expressed in MC38 cells represents a mutant or nonmutant tumor Ag, we sequenced the expressed env sequence and compared it with the published sequence, derived from the AKR mouse strain, 41 and with the endogenous sequence in C57BL/6 genomic DNA. The full-length env cDNA was amplified from MC38 total RNA by PCR after reverse transcription. The normal sequence was amplified from genomic DNA extracted from a C57BL/6 mouse. Previously reported coding sequence differences between B16 env (also derived from a C57BL/6 mouse) and that of the AKV 44 were either not found in the MC38 expressed sequence (nucleotides 6116, 6419, 7017, and 7085 41 ) or found to be the same in the MC38-derived env and the C57BL/6 genomic sequence. Thus the differences between the MC38 and AKR-derived sequences likely represent variations between the mouse strains. Also of note, as reported by others, 44, 46 the env gene expressed in MC38 cells has a 99-bp deletion in the 3Ј LTR compared with AKV; however, this change also appeared to be present in the C57BL/6 genomic sequences when size was examined by PCR (data not shown).
Polynucleotide immunization
As both a preliminary and rapid means of assessing the potential of the env polypeptide to act as an immunogenic tumor Ag, the 1.3-kb insert was rescued as phagemid DNA from the reactive plaque and used for polynucleotide immunization. Mice were immunized with the env-encoding DNA, and Ab production was subsequently measured. Intramuscular immunization of C57BL/6 mice with the nonmutant env sequence elicited a strong, specific anti-env Ab response in all immunized mice (Fig 5) . By contrast, animals immunized with the vector alone exhibited no reactivity with the env protein.
Isotype analysis of the anti-env Ab response revealed the presence of several isotypes, including IgG1, IgG2a, and IgG2b, suggesting the presence of both Th1 and Th2 type responses. 48, 49 
DISCUSSION
A limited number of murine tumor Ags have been described to date, and the ability of these Ags to elicit effective antitumoral immunity is currently an area of active investigation. Although prospects for the development of immunotherapeutic modalities have recently been improved by advances in the field of immunology, 50, 51 knowledge of the spectrum of tumor Ags important in mediating immune interactions is needed. In addition, it is important to catalog the nature of murine tumor Ags, such that a comparison with human cancers can be explored and more appropriate animal models can be developed for evaluating immunotherapeutic approaches to cancer. We have used a strategy for tumor Ag identification that exploits the humoral immune responses that accompany the induction of antitumoral immunity and have identified the MuLV endogenous ecotropic env gene-encoded protein and the ATRX protein as candidate tumor Ags in MC38 colon adenocarcinoma cells.
The ATRX protein is expressed in a wide variety of normal tissues in mice and humans. 52 This protein contains highly conserved domains, which classify it as a member of the helicase/adenosine triphosphatase superfamily. 53 It thought to be a nuclear protein involved in the regulation of gene expression. 42, 54 In humans, a deficiency in this protein is associated with a severe mental retardation syndrome (ATR-X syndrome) which includes ␣-thalassemia, urogenital abnormalities, and a characteristic facial appearance. A role for ATRX in cancer has not yet been described. Northern blot analysis demonstrates that this gene is expressed to a variable degree in all murine tumor lines tested. No mutations were identified in the partial cDNA isolated, and additional studies are underway to determine the basis of this protein's immunogenicity as well as to evaluate the potential of ATRX to serve as a tumor Ag.
More is known about the role of the env protein as a potential tumor Ag. This protein is encoded by one of the numerous endogenous retroviral sequences present in the normal mouse genome. Endogenous retroviruses are relatively stable elements that are present in multiple copies throughout the genome and inherited in a Mendelian fashion. 55 C57BL/6 mice carry a single copy of an endogenous ecotropic virus, and it is defective and transcriptionally silent in normal tissues. 44 Activation of endogenous retroviruses spontaneously or after exposure to carcinogens has been described in several mouse strains. Activation may occur by several mechanisms, including point mutation, 45 transcomplementation or recombination with other endogenous retroviruses, 56 -58 or by amplification and rearrangement of the locus. 46 Here, activation of env expression in MC38 cells is associated with the appearance of novel bands on Southern blot analysis, suggesting that amplification and reintegration events are likely to have occurred. The exact nature of the activating mutation(s) will require further study.
Although the env protein was identified in this study on the basis of humoral immunity, it has been determined to be a target of CTL activity in both C57BL/6 mice 44 and BALB/c mice. 59 The identification of a CTL-activating protein by immunoscreening supports the use of Ab-based screening for the identification of relevant tumor Ags. Further, although most murine tumor Ags are thought to be unique to a particular tumor, 60, 61 our findings suggest that env is expressed in several murine tumors. This Ag is expressed in both spontaneous and mutagen-induced tumor cell lines derived from mice of different genetic backgrounds and from a variety of tissue types (Fig 3A) . Sequence analysis revealed no apparent differences between the sequences expressed in the MC38 cells and the genomic sequences of the env gene, suggesting that this Ag is a true "self" Ag. Thus, env is immunogenic based on its expression in the tumor. Polynucleotide immunization demonstrated that this protein is capable of acting as an immunogen in C57BL/6 mice. A specific IgG Ab response was elicited in all immunized mice. Interestingly, this Ag may also have relevance to human cancer. The human homologs of the env gene, contained in human endogenous retroviral elements (HERVs), may also act as tumor Ags. HERVs are also widely dispersed throughout the human genome. Unlike mice, however, expression of a few of these proviral sequences has been reported in some normal human tissues, most notably placenta. 62 HERV expression has also been noted in a variety of tumor cell lines. Recently, Abs to the HERVK10 env sequence were reported to be present in a large percentage of patients with seminoma. 63 These attributes may make this tumor Ag an ideal target for additional studies relevant to tumor vaccinology.
In summary, application of SEREX to mouse models of carcinoma offers a comparatively rapid means of Figure 5 . Induction of a humoral immune response to the env protein after polynucleotide immunization. Sera from four mice immunized with the 1.3-kb env cDNA (E1-E4) were incubated with filter lifts of phage encoding the env protein mixed with an approximately equal ratio of control, negative phage. Half of the plaques (encoding env) are strongly reactive, demonstrating the specificity of the reaction. Sera from mice immunized with an empty phagemid vector (N1-N4) were used for screening in the same manner, and did not contain Abs that recognize the env protein.
identifying putative tumor Ags, which can then be evaluated for utility in gene therapy approaches to cancer immunotherapy. The development of more accurate preclinical models for the evaluation of improved vaccination strategies is one important goal of such studies. This approach may also be important for expanding known human tumor Ags through the identification of murine homologs.
